With regard to the localization of the mutations identified in non-GC cancers, we verified that the majority of CDH1 mutations affected the extracellular domain (31/54, 57.4%), followed by precursor (13/54, 24.1%), signal (6/54, 11.1%), cytoplasmic (3/54, 5.6%), and transmembrane (1/54, 1.8%) domains (Figure 2). This evidence concerns the gene CDH1 and cancer.